Post Market Clinical Evaluation of Gamma 4

Last updated: March 18, 2025
Sponsor: Stryker Trauma and Extremities
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

N/A

Treatment

Gamma4 Nailing System

Clinical Study ID

NCT05523635
TA-01-2022
  • Ages > 18
  • All Genders

Study Summary

This is a prospective, multi-center, non-randomized, post-market clinical investigation of the Gamma 4 System. Neither subjects nor investigators are blinded to treatment.

It is anticipated that a total of 100 subjects will be enrolled at five sites. Total duration of enrollment, 12 month follow-up and analysis is expected to take approximately 30 months. The clinical investigation has been designed to follow the surgeon's standard of care for subjects treated with a cephalomedullary nail for femoral fractures or and deformities, in addition to a 12 month follow-up visit.

The primary endpoint of this clinical investigation is demonstration of bone consolidation by 12 months.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Subject is a male or non-pregnant female age 18 years or older at the time ofsurgery;

  • Subject is willing and able to give written informed consent and comply with therequirements of this Clinical Investigation Plan; and

  • Subject has or is intended to be treated with the Gamma 4 System in accordance withits legally approved Indication for Use (IFU).

Indication For Use in the United States and Canada:

The Gamma4 System is indicated for the treatment of stable and unstable fractures as well as for stabilization of bones and correction of bone deformities in the intracapsular, trochanteric, subtrochanteric and shaft regions of the femur (including osteoporotic and osteopenic bone).

Exclusion

Exclusion Criteria:

  • Subject is currently enrolled in or plans to enroll in any concurrent drug and/ordevice clinical investigation that, in the opinion of the Investigator, may confoundresults

  • Subject with exclusion criteria required by local law

  • Subject who is, or will be, inaccessible for follow-up

  • Per the Investigator, the subject is in poor general health or undergoing anyconcurrent disease that would place the subject in excessive risk to surgery (i.e.,significant circulatory problems, cardiac disease).

  • Any active or suspected latent infection or marked local inflammation in or aboutthe affected area

  • Compromised vascularity that would inhibit adequate blood supply to the fracture orthe operative site

  • Bone stock compromised by disease, infection or prior implantation that cannotprovide adequate support and/or fixation of the devices

  • Material sensitivity, documented or suspected

  • Patients having inadequate tissue coverage over the operative site

  • Implant utilization that would interfere with anatomical structures or physiologicalperformance

  • Any mental or neuromuscular disorder which would create an unacceptable risk offixation failure or complications in postoperative care

  • Other medical or surgical conditions which would preclude the potential benefit ofsurgery.

Study Design

Total Participants: 100
Treatment Group(s): 1
Primary Treatment: Gamma4 Nailing System
Phase:
Study Start date:
March 06, 2023
Estimated Completion Date:
October 31, 2025

Study Description

The objective of this clinical investigation is to demonstrate the safety and efficacy/performance of the Gamma 4 System. Enrolled subjects will undergo an initial assessment, with follow-up evaluations at 3 Months, 6 Months, and 12 Months after the index procedure.

The primary endpoint of this clinical investigation is demonstration of bone consolidation by 12 months, as measured by the Investigator.

Secondary endpoints will include safety through reporting the incidence of device related intra-operative and post-operative adverse events by 12 months, patient reported outcome measures (SF-35v2 and Modified Harris Hip Score), and other specific health outcomes.

Efficacy will be assessed through non-inferiority of bone consolidation proportion compared to the pooled literature control, as well as the SF-36 score results by 12 months.

Connect with a study center

  • William Beaumont Hospital

    Royal Oak, Michigan 48073
    United States

    Site Not Available

  • MetroHealth

    Cleveland, Ohio 44109
    United States

    Site Not Available

  • UT Health

    San Antonio, Texas 78229
    United States

    Site Not Available

  • Inova Health Care Services

    Falls Church, Virginia 22042
    United States

    Site Not Available

  • SSM Health - Madison

    Madison, Wisconsin 53715
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.